Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma
A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL—short for trimeric APRIL (a proliferation-inducing ligand)—recognizes two proteins on myeloma cells instead of just one. Researchers…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.